Efficacy and safety of galantamine reminyl for d

Authors: I V Litvinenko M M Odinak V I Mogil’naya A Yu Emelin

Publish Date: 2008/10/31

Volume: 38, Issue: 9, Pages: 937-

PDF Link

Abstract

An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinsons disease with dementia randomized to a galantamine treatment group 21 patients and a control group 20 patients Cognitive neuropsychiatric and motor symptoms were assessed clinically before the trial and at 4 12 and 24 weeks using the Mini Mental State Examination MMSE the cognitive Alzheimers Disease Assessment Scale ADAScog the clock drawing test the Frontal Assessment Battery FAB and the Neuropsychiatric Inventory NPI with assessment of distress in relatives Patients treated with galantamine had better scores on the MMSE p 005ADAScog p 005 the clock drawing test p 005 and the FAB p 001 at the end of the study period as compared with the control group Changes in total point scores on the NPI12 at the ends of weeks 12 and 24 as compared with the beginning of the trial were in favor of the group treated with galantamine with significant changes in the hallucinations p = 00002 anxiety p = 004 sleep disturbance p = 004 and apathy p = 0006 sections Galantamine treatment was accompanied by decreases in the level of distress in patients relatives p = 0007 and improvements in daily activity p = 0003 Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group However two patients of this group showed minor increases in tremor Side effects drooling postural hypotension nausea dysuria occurred in seven patients 30

Keywords: